FDA
-
-
-
-
-
-
-
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
-
-
-
-
-
-
-
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
-
-
-
-
-
-
-
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
-
-
-
-
-
-
-
Azitra, Inc. Addresses False Report Regarding Sale of Securities
-
-
-
-
-
-
-
Azitra doses first patient in trial for cancer rash treatment
-
-
-
-
-
-
-
Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
-
-
-
-
-
-
-
Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates
-
329,957 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

